Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation: Comparison with conventional regimen

Kanayo Takahashi, Yoshihiko Soga, Yumeno Murayama, Mika Udagawa, Hitomi Nishimoto, Yuko Sugiura, Yoshinobu Maeda, Mitsune Tanimoto, Shogo Takashiba

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Goals of work: Severe oral mucositis induced by allogeneic hematopoietic cell transplantation (HCT) is associated with intolerable pain and risk of systemic bacteremia infection. Differences between conventional HCT and reduced-intensity regimens for allogeneic HCT (RIST) may influence the occurrence and severity of oral mucositis. Here, we evaluated oral mucositis in patients undergoing RIST and compared the results with those in conventional allogeneic HCT patients to facilitate predictive measures for mucositis. Patients and methods: A total of 127 consecutive patients undergoing HCT (conventional, 63; RIST, 64) were included in this study. Severity of oral mucositis during HCT period was evaluated daily. Differences in severity of mucositis among HCT types were analyzed. Use of morphine to control pain due to oral mucositis was evaluated in each HCT method. Main results: The severity of oral mucositis was reduced in patients undergoing RIST. Worsening of oral mucositis was delayed in patients receiving RIST. Use of morphine to control pain due to oral mucositis was significantly decreased in patients undergoing RIST compared with those receiving conventional allogeneic HCT. Conclusions: The severity of oral mucositis was reduced and the peak day of oral mucositis was delayed in RIST patients compared with those receiving conventional HCT.

Original languageEnglish
Pages (from-to)115-119
Number of pages5
JournalSupportive Care in Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Stomatitis
Cell Transplantation
Mucositis
Pain
Morphine
Bacteremia

Keywords

  • Hematopoietic cell transplantation
  • Oral mucositis
  • Reduced-intensity regimens

ASJC Scopus subject areas

  • Oncology

Cite this

Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation : Comparison with conventional regimen. / Takahashi, Kanayo; Soga, Yoshihiko; Murayama, Yumeno; Udagawa, Mika; Nishimoto, Hitomi; Sugiura, Yuko; Maeda, Yoshinobu; Tanimoto, Mitsune; Takashiba, Shogo.

In: Supportive Care in Cancer, Vol. 18, No. 1, 01.2010, p. 115-119.

Research output: Contribution to journalArticle

@article{65dd3126e7c746eebee0c6ed9986ca59,
title = "Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation: Comparison with conventional regimen",
abstract = "Goals of work: Severe oral mucositis induced by allogeneic hematopoietic cell transplantation (HCT) is associated with intolerable pain and risk of systemic bacteremia infection. Differences between conventional HCT and reduced-intensity regimens for allogeneic HCT (RIST) may influence the occurrence and severity of oral mucositis. Here, we evaluated oral mucositis in patients undergoing RIST and compared the results with those in conventional allogeneic HCT patients to facilitate predictive measures for mucositis. Patients and methods: A total of 127 consecutive patients undergoing HCT (conventional, 63; RIST, 64) were included in this study. Severity of oral mucositis during HCT period was evaluated daily. Differences in severity of mucositis among HCT types were analyzed. Use of morphine to control pain due to oral mucositis was evaluated in each HCT method. Main results: The severity of oral mucositis was reduced in patients undergoing RIST. Worsening of oral mucositis was delayed in patients receiving RIST. Use of morphine to control pain due to oral mucositis was significantly decreased in patients undergoing RIST compared with those receiving conventional allogeneic HCT. Conclusions: The severity of oral mucositis was reduced and the peak day of oral mucositis was delayed in RIST patients compared with those receiving conventional HCT.",
keywords = "Hematopoietic cell transplantation, Oral mucositis, Reduced-intensity regimens",
author = "Kanayo Takahashi and Yoshihiko Soga and Yumeno Murayama and Mika Udagawa and Hitomi Nishimoto and Yuko Sugiura and Yoshinobu Maeda and Mitsune Tanimoto and Shogo Takashiba",
year = "2010",
month = "1",
doi = "10.1007/s00520-009-0637-z",
language = "English",
volume = "18",
pages = "115--119",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation

T2 - Comparison with conventional regimen

AU - Takahashi, Kanayo

AU - Soga, Yoshihiko

AU - Murayama, Yumeno

AU - Udagawa, Mika

AU - Nishimoto, Hitomi

AU - Sugiura, Yuko

AU - Maeda, Yoshinobu

AU - Tanimoto, Mitsune

AU - Takashiba, Shogo

PY - 2010/1

Y1 - 2010/1

N2 - Goals of work: Severe oral mucositis induced by allogeneic hematopoietic cell transplantation (HCT) is associated with intolerable pain and risk of systemic bacteremia infection. Differences between conventional HCT and reduced-intensity regimens for allogeneic HCT (RIST) may influence the occurrence and severity of oral mucositis. Here, we evaluated oral mucositis in patients undergoing RIST and compared the results with those in conventional allogeneic HCT patients to facilitate predictive measures for mucositis. Patients and methods: A total of 127 consecutive patients undergoing HCT (conventional, 63; RIST, 64) were included in this study. Severity of oral mucositis during HCT period was evaluated daily. Differences in severity of mucositis among HCT types were analyzed. Use of morphine to control pain due to oral mucositis was evaluated in each HCT method. Main results: The severity of oral mucositis was reduced in patients undergoing RIST. Worsening of oral mucositis was delayed in patients receiving RIST. Use of morphine to control pain due to oral mucositis was significantly decreased in patients undergoing RIST compared with those receiving conventional allogeneic HCT. Conclusions: The severity of oral mucositis was reduced and the peak day of oral mucositis was delayed in RIST patients compared with those receiving conventional HCT.

AB - Goals of work: Severe oral mucositis induced by allogeneic hematopoietic cell transplantation (HCT) is associated with intolerable pain and risk of systemic bacteremia infection. Differences between conventional HCT and reduced-intensity regimens for allogeneic HCT (RIST) may influence the occurrence and severity of oral mucositis. Here, we evaluated oral mucositis in patients undergoing RIST and compared the results with those in conventional allogeneic HCT patients to facilitate predictive measures for mucositis. Patients and methods: A total of 127 consecutive patients undergoing HCT (conventional, 63; RIST, 64) were included in this study. Severity of oral mucositis during HCT period was evaluated daily. Differences in severity of mucositis among HCT types were analyzed. Use of morphine to control pain due to oral mucositis was evaluated in each HCT method. Main results: The severity of oral mucositis was reduced in patients undergoing RIST. Worsening of oral mucositis was delayed in patients receiving RIST. Use of morphine to control pain due to oral mucositis was significantly decreased in patients undergoing RIST compared with those receiving conventional allogeneic HCT. Conclusions: The severity of oral mucositis was reduced and the peak day of oral mucositis was delayed in RIST patients compared with those receiving conventional HCT.

KW - Hematopoietic cell transplantation

KW - Oral mucositis

KW - Reduced-intensity regimens

UR - http://www.scopus.com/inward/record.url?scp=71349085987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71349085987&partnerID=8YFLogxK

U2 - 10.1007/s00520-009-0637-z

DO - 10.1007/s00520-009-0637-z

M3 - Article

C2 - 19387694

AN - SCOPUS:71349085987

VL - 18

SP - 115

EP - 119

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 1

ER -